Metástasis

Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors

Retrieved on: 
Monday, October 5, 2020
Immunocore, Metástasis, Medicine, Health

ST. LOUIS, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the treatment of solid and metastatic cancers, has bolstered its expertise through the appointment of Jonathan Knowles, Ph.D. to its Board of Directors.

Key Points: 
  • ST. LOUIS, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the treatment of solid and metastatic cancers, has bolstered its expertise through the appointment of Jonathan Knowles, Ph.D. to its Board of Directors.
  • Dr. Knowles has made instrumental contributions in developing and commercializing multiple drugs in several therapeutic areas.
  • His insights will be invaluable in advancing IP-001 through clinical development and commercialization, stated Dr. Bobby W. Sandage, Jr., Immunophotonics Chairman of the Board.
  • Most recently, he has served as Chairman of the Board for Immunocore Ltd. and Adaptimmune Ltd., two major UK biotech companies.

Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors

Retrieved on: 
Monday, October 5, 2020
Immunocore, Metástasis, Medicine, Health

BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the treatment of solid and metastatic cancers, has bolstered its expertise through the appointment of Jonathan Knowles, Ph.D. to its Board of Directors.

Key Points: 
  • BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the treatment of solid and metastatic cancers, has bolstered its expertise through the appointment of Jonathan Knowles, Ph.D. to its Board of Directors.
  • Dr. Knowles has made instrumental contributions in developing and commercializing multiple drugs in several therapeutic areas.
  • His insights will be invaluable in advancing IP-001 through clinical development and commercialization, stated Dr. Bobby W. Sandage, Jr., Immunophotonics Chairman of the Board.
  • Most recently, he has served as Chairman of the Board for Immunocore Ltd. and Adaptimmune Ltd., two major UK biotech companies.

#LightUpMBC Shines a Light on the Importance of Awareness and Funding For Metastatic Breast Cancer with Over 115 Landmarks Worldwide Illuminated in Green, Teal and Pink

Retrieved on: 
Friday, October 2, 2020
Breast cancer, RTT, Cancer, Health, Medical specialties, Oncology, Metastatic breast cancer, Metástasis, Breast cancer awareness, Breast cancer management

METAvivor President Jamil Rivers says, "Metastatic breast cancer (MBC), also known as stage 4 breast cancer, is not curable and means the cancer cells have left the breast and spread to other parts of the body.

Key Points: 
  • METAvivor President Jamil Rivers says, "Metastatic breast cancer (MBC), also known as stage 4 breast cancer, is not curable and means the cancer cells have left the breast and spread to other parts of the body.
  • Metastatic breast cancer (MBC) is stage 4 breast cancer, for which there is no cure.
  • 98% of all breast cancer related deaths are from MBC, yet less than 5% of overall breast cancer research is currently allocated to researching metastatic breast cancer.
  • About METAvivor and the Origin of the Metastatic Breast Cancer (MBC) Ribbon:
    METAvivor puts 100% of every donation toward stage 4 metastatic breast cancer research.

ISB Researchers Identify Signals of Metastatic Cancer Years Prior to Diagnosis

Retrieved on: 
Thursday, October 1, 2020
Clinical medicine, Branches of biology, RTT, Medicine, Oncology, Biomarkers, Cancer biomarker, Metastatic breast cancer, Cancer, Metástasis, Pancreatic cancer, Breast cancer

One protein -- CEACAM5 -- was a persistent outlier for every metastatic diagnosis (breast, lung and pancreatic cancers), and appeared as early as 26.5 months before diagnosis.

Key Points: 
  • One protein -- CEACAM5 -- was a persistent outlier for every metastatic diagnosis (breast, lung and pancreatic cancers), and appeared as early as 26.5 months before diagnosis.
  • Two proteins -- CALCA and DLK1 -- were specific to metastatic pancreatic cancer, and were outliers at least 16.5 months before diagnosis.
  • Another protein -- ERBB2 -- was specific to metastatic breast cancer, and spiked significantly between 10 and four months before diagnosis.
  • Typically, studies seeking to identify cancer biomarkers compare samples of diagnosed cancer patients with non-cancer controls.

Beyond Air® to Present Data on Nitric Oxide in the Treatment of Solid Tumors at the American Association for Cancer Research (AACR) Conference on Tumor Immunology and Immunotherapy

Retrieved on: 
Wednesday, September 30, 2020
Medical specialties, RTT, Clinical medicine, Medicine, Oncology, Bacteriology, Nontuberculous mycobacteria, Metástasis, Cancer, Metastatic breast cancer

Beyond Air is currently advancing its revolutionary LungFit for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM).

Key Points: 
  • Beyond Air is currently advancing its revolutionary LungFit for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM).
  • Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.
  • Cancer is the second leading cause of death globally, with tumor metastases responsible for approximately 90% of all cancer-related deaths.
  • Based on its current findings, Beyond Air is developing treatment protocols using ultra-high nitric oxide concentrations to ablate primary tumors and treat metastatic disease.

Lantheus Holdings Submits New Drug Application to the U.S. FDA for PyL™ (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent

Retrieved on: 
Wednesday, September 30, 2020
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Cancer, Anatomy, Branches of biology, Histopathology, Prostate cancer, RTT, Oncology, Prostate, Metástasis, Management of prostate cancer, Prostate-specific antigen, PyL™ for PET Imaging of Prostate Cancer, OSPREY, CONDOR, Prostate Cancer, Lantheus Holdings, Inc.

The NDA is supported by data from two pivotal studies (OSPREY and CONDOR), designed to establish the safety and diagnostic performance of PyL imaging across the disease continuum of prostate cancer.

Key Points: 
  • The NDA is supported by data from two pivotal studies (OSPREY and CONDOR), designed to establish the safety and diagnostic performance of PyL imaging across the disease continuum of prostate cancer.
  • Results from OSPREY Cohort A demonstrated improvement in specificity and positive predictive value (PPV) of PyL PET imaging over conventional imaging in men with high risk prostate cancer.
  • OSPREY Cohort B and CONDOR studied men with prostate cancer in various disease states, including biochemical recurrent prostate cancer, hormone sensitive prostate cancer, non-metastatic castrate resistant prostate cancer, and metastatic castrate resistant prostate cancer.
  • In the CONDOR study, 63.9% of patients had a change in intended disease management plans due to the PyL imaging results.

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1

Retrieved on: 
Tuesday, September 22, 2020
Cancer, Oncology, Clinical medicine, Medicine, Cancer pathology, Cancer treatments, Antineoplastic drugs, Invasión, E-selectin, Metástasis, Chemotherapy

15/748,784) on anti-neoplastic compounds and methods targeting Quiescin Sulfhydryl Oxidase 1 (QSOX1), an enzyme important for tumor cell growth, invasion and metastasis.

Key Points: 
  • 15/748,784) on anti-neoplastic compounds and methods targeting Quiescin Sulfhydryl Oxidase 1 (QSOX1), an enzyme important for tumor cell growth, invasion and metastasis.
  • SBI-183 selectively targets QSOX1 and, in animal models, has been found to inhibit tumor growth, invasion and suppress metastasis of tumors by inactivating QSOX1.
  • At our core, we are an oncology company dedicated to reducing metastasis in cancer patients around the world.
  • Currently, SPX-1009 has proven itself to be tenfold more potent in suppressing tumor invasion and metastasis in vitro than SBI-183.

New Data Support Strong Clinical Profile of Vitrakvi® (larotrectinib) for Adult and Pediatric Patients with TRK Fusion Cancer, Including Lung and Thyroid Tumors

Retrieved on: 
Thursday, September 17, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cancer, Clinical medicine, Medicine, Oncology, Larotrectinib, Metástasis, Vitrakvi® (larotrectinib), TRK Fusion Cancer, Oncology at Bayer, Bayer

These data affirm Vitrakvis robust clinical profile with the largest dataset and longest follow-up of any TRK inhibitor and reinforce our longstanding commitment to developing innovative treatments for patients.

Key Points: 
  • These data affirm Vitrakvis robust clinical profile with the largest dataset and longest follow-up of any TRK inhibitor and reinforce our longstanding commitment to developing innovative treatments for patients.
  • For patients with CNS metastases, the ORR was 57% (95% CI 18-90; no patients with CR, n=4/7 with PRs).
  • In the analysis of 122 adult and pediatric patients with metastatic and locally advanced disease treated with Vitrakvi, the median GMI was 3.35 (range 0.00-337).
  • Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients.

Delcath Systems, Inc. to Participate in Upcoming Virtual Investor Conferences

Retrieved on: 
Thursday, September 10, 2020
Medical specialties, Health, Medicine, Oncology, RTT, Delcath Systems, Interventional oncology, Metástasis, Cancer

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will participate in two upcoming virtual investor conferences:

Key Points: 
  • NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will participate in two upcoming virtual investor conferences:
    H.C. Wainwright 22nd Annual Global Investment Conference, presenting on Tuesday, September 15 at 4:30 PM (EDT).
  • A live webcast of the presentation will be available to the public at https://wsw.com/webcast/hcw7/dcth/1592203
    Oppenheimer Fall Healthcare Life Science & Med Tech Summit, participating on September 23, 2020.
  • Management will be available for virtual one-on-one meetings during both conferences.
  • Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.

Black People More Likely Than Others to Die From Colorectal Cancer Spreading to the Liver

Retrieved on: 
Wednesday, September 9, 2020
Oncology, Health, Other Health, Other Science, Research, Science, Medical specialties, Clinical medicine, Medicine, Hepatology, RTT, Surgical oncology, Infectious causes of cancer, Metastatic liver disease, Cancer, Colorectal cancer, Hepatectomy, Metástasis

The unfortunate reality is that minorities, especially Black people, have a much lower chance of getting lifesaving cancer treatment.

Key Points: 
  • The unfortunate reality is that minorities, especially Black people, have a much lower chance of getting lifesaving cancer treatment.
  • We observed that if Black people with metastatic colorectal cancer had access to subspecialists with expertise in liver resection, they would not experience higher numbers of unnecessary deaths due to underutilization of lifesaving therapies.
  • The finding potentially has broad reach considering colorectal cancer is the third leading cause of cancer-related deaths in the United States (excluding some kinds of skin cancer).
  • There is a vast under-utilization of liver resection as a potentially curative treatment for colorectal liver metastases, Fong said.